Law360, New York (April 21, 2011, 4:47 PM ET) -- A federal judge in California on Thursday cleared the way for Sanofi-Aventis Deutschland GmbH to appeal a decision that two Genentech Inc.'s cancer drugs do not infringe the pharmaceutical giant's patents.
The decision to grant Sanofi final judgment allows the company to immediately appeal a March ruling in support of Genentech, which was seeking judgment that its Rituxan and Avastin drugs did not infringe two patents, and halted nearly all court proceedings.
Sanofi and Genentech have wrangled over U.S. Patent Numbers 5,849,522 and 6,218,140, which pertain...
Sanofi Free To Appeal Genentech Patent Ruling
To view the full article, take a free trial now.
